Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
04:05pm, Wednesday, 29'th Apr 2026
First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health of $1,423
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmo
The skin recovery emulsion for dry, sensitive, or stressed skin is now available through select online channels LAVAL, QC, April 14, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BH
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update
07:00am, Wednesday, 08'th Apr 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S.
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe
07:00am, Tuesday, 07'th Apr 2026
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European comme
Bausch Health to Announce First Quarter 2026 Results on April 29, 2026
07:00am, Tuesday, 31'st Mar 2026
LAVAL, QC, March 31, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release first quarter 2026 financial results after market close on Wednesday, April 29, 2026. Bausch Hea
Bausch Health Announces Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program
08:00am, Thursday, 26'th Mar 2026
Bausch Health is offering scholarships to six students impacted by dermatologic conditions, with applications open through June 2026 LAVAL, QC, March 26, 2026 /PRNewswire/ -- Bausch Health Companies I
Is the Options Market Predicting a Spike in Bausch Health Stock?
05:36pm, Tuesday, 24'th Mar 2026
Investors need to pay close attention to BHC stock based on the movements in the options market lately.
Bausch (BHC) Down 15.2% Since Last Earnings Report: Can It Rebound?
12:31pm, Friday, 20'th Mar 2026
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm
09:00am, Friday, 13'th Mar 2026
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation , (“ BLCO " or the "Company") ( NYSE : BLCO ) investors that the firm has initiated an investig
Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant® Touch Laser in Canada
08:00am, Monday, 23'rd Feb 2026
LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today
Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?
12:01pm, Friday, 20'th Feb 2026
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.
Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats
02:54pm, Thursday, 19'th Feb 2026
Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum,
BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth
01:01pm, Thursday, 19'th Feb 2026
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.
How Bausch Health's Turnaround Progressed In Q4 2025
10:07am, Thursday, 19'th Feb 2026
How Bausch Health's Turnaround Progressed In Q4 2025
